Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × canakinumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 4 Triple Negative Breast Neoplasms 1 Rheumatoid Arthritis, Systemic Juvenile 1 Rectal Neoplasms 1 Primary Myelofibrosis 1 Periodic Fevers Syndrome 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Mevalonate Kinase Deficiency 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Melanoma 1 Leukemia, Myelomonocytic, Chronic 1 Intestinal Neoplasms 1 Gastrointestinal Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Clonal Cytopenia of Undetermined Significance 1 Carcinoma, Renal Cell 1 Carcinoma, Ductal 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 Arthritis, Juvenile 1 Arthralgia 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

pembrolizumab 268 Nivolumab 241 Ipilimumab 221 aldesleukin 126 Cyclophosphamide 126 Interleukin-2 93 trametinib 76 dabrafenib 68 Dacarbazine 68 Temozolomide 66 fludarabine 64 Vemurafenib 64 fludarabine phosphate 56 Biopsy 45 Radiosurgery 43 sargramostim 40 Bevacizumab 40 binimetinib 39 incomplete Freund's adjuvant 37 Paclitaxel 35 atezolizumab 34 Radiotherapy 34 Cisplatin 34 Blood Specimen Collection 33 encorafenib 32 Magnetic Resonance Spectroscopy 32 cobimetinib 31 Specimen Handling 31 Introns 31 Carboplatin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡